Development of Sustained Release "NanoFDC (Fixed Dose Combination)" for Hypertension - An Experimental Study

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2015 Jun 6

PMID 26047011

Citations 5

Authors

Anjuman Arora

Nusrat Shafiq

Sanjay Jain

G K Khuller

Sadhana Sharma

Samir Malhotra

Affiliations

Soon will be listed here.

Abstract

Objectives: The present study was planned to formulate, characterize and evaluate the pharmacokinetics of a novel "NanoFDC" comprising three commonly prescribed anti-hypertensive drugs, hydrochlorothiazide (a diuretic), candesartan (ARB) and amlodipine (a calcium channel blocker).

Basic Methods: The candidate drugs were loaded in Poly (DL-lactide-co-gycolide) (PLGA) by emulsion- diffusion-evaporation method. The formulations were evaluated for their size, morphology, drug loading and in vitro release individually. Single dose pharmacokinetic profiles of the nanoformulations alone and in combination, as a NanoFDC, were evaluated in Wistar rats.

Results: The candidate drugs encapsulated inside PLGA showed entrapment efficiencies ranging from 30%, 33.5% and 32% for hydrochlorothiazide, candesartan and amlodipine respectively. The nanoparticles ranged in size from 110 to 180 nm. In vitro release profile of the nanoformulation showed 100% release by day 6 in the physiological pH 7.4 set up with PBS (phosphate buffer saline) and by day 4-5 in the intestinal pH 1.2 and 8.0 set up SGF (simulated gastric fluid) and SIF (simulated intestinal fluid) respectively. In pharmacokinetic analysis a sustained-release for 6 days and significant increase in the mean residence time (MRT), as compared to the respective free drugs was noted [MRT of amlodipine, hydrochlorothiazide and candesartan changed from 8.9 to 80.59 hours, 11 to 69.20 hours and 9 to 101.49 hours respectively].

Conclusion: We have shown for the first time that encapsulating amlodipine, hydrochlorothiazide and candesartan into a single nanoformulation, to get the "NanoFDC (Fixed Dose Combination)" is a feasible strategy which aims to decrease pill burden.

Citing Articles

Targeted therapy in chronic diseases using nanomaterial-based drug delivery vehicles.

Singh A, Biswas A, Shukla A, Maiti P Signal Transduct Target Ther. 2019; 4:33.

PMID: 31637012 PMC: 6799838. DOI: 10.1038/s41392-019-0068-3.

Potential Strategies to Reduce Blood Pressure in Treatment-Resistant Hypertension Using Food and Drug Administration-Approved Nanodrug Delivery Platforms.

Fancher I, Rubinstein I, Levitan I Hypertension. 2019; 73(2):250-257.

PMID: 30624988 PMC: 6338082. DOI: 10.1161/HYPERTENSIONAHA.118.12005.

Bio Pharmaceutics Classification System (BCS) Class IV Drug Nanoparticles: Quantum Leap to Improve Their Therapeutic Index.

Kumar S, Kaur R, Rajput R, Singh M Adv Pharm Bull. 2019; 8(4):617-625.

PMID: 30607334 PMC: 6311639. DOI: 10.15171/apb.2018.070.

Nanocarriers as treatment modalities for hypertension.

Alam T, Khan S, Gaba B, Haider M, Baboota S, Ali J Drug Deliv. 2017; 24(1):358-369.

PMID: 28165823 PMC: 8241143. DOI: 10.1080/10717544.2016.1255999.

Preparation of Hydrochlorothiazide Nanoparticles for Solubility Enhancement.

Vaculikova E, Cernikova A, Placha D, Pisarcik M, Peikertova P, Dedkova K Molecules. 2016; 21(8).

PMID: 27490530 PMC: 6274297. DOI: 10.3390/molecules21081005.

References

Thrall G, Lip G, Lane D . Compliance with pharmacological therapy in hypertension: can we do better, and how?. J Hum Hypertens. 2004; 18(9):595-7. DOI: 10.1038/sj.jhh.1001722. View

Dickson M, Plauschinat C . Compliance with antihypertensive therapy in the elderly: a comparison of fixed-dose combination amlodipine/benazepril versus component-based free-combination therapy. Am J Cardiovasc Drugs. 2008; 8(1):45-50. DOI: 10.2165/00129784-200808010-00006. View

James P, Oparil S, Carter B, Cushman W, Dennison-Himmelfarb C, Handler J . 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2013; 311(5):507-20. DOI: 10.1001/jama.2013.284427. View

Khan M, Shah S, Hameed T . Barriers to and determinants of medication adherence among hypertensive patients attended National Health Service Hospital, Sunderland. J Pharm Bioallied Sci. 2014; 6(2):104-8. PMC: 3983739. DOI: 10.4103/0975-7406.129175. View

Kumar G, Sharma S, Shafiq N, Khuller G, Malhotra S . Optimization, in vitro-in vivo evaluation, and short-term tolerability of novel levofloxacin-loaded PLGA nanoparticle formulation. J Pharm Sci. 2012; 101(6):2165-76. DOI: 10.1002/jps.23087. View

Chobanian A, Bakris G, Black H, Cushman W, Green L, Izzo Jr J . The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003; 289(19):2560-72. DOI: 10.1001/jama.289.19.2560. View

Wald N, Law M . A strategy to reduce cardiovascular disease by more than 80%. BMJ. 2003; 326(7404):1419. PMC: 162259. DOI: 10.1136/bmj.326.7404.1419. View

Tocci G, Volpe M . Modern clinical management of arterial hypertension: fixed or free combination therapies?. High Blood Press Cardiovasc Prev. 2011; 18 Suppl 1:3-11. DOI: 10.2165/1159615-s0-000000000-00000. View

Pandey R, Sharma S, Khuller G . Oral poly(lactide-co-glycolide) nanoparticle based antituberculosis drug delivery: toxicological and chemotherapeutic implications. Indian J Exp Biol. 2006; 44(6):459-67. View

10.

Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G . 2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension. J Hypertens. 2007; 25(9):1751-62. DOI: 10.1097/HJH.0b013e3282f0580f. View

11.

Sanz G, Fuster V . Fixed-dose combination therapy and secondary cardiovascular prevention: rationale, selection of drugs and target population. Nat Clin Pract Cardiovasc Med. 2008; 6(2):101-10. DOI: 10.1038/ncpcardio1419. View

12.

Heng D, Cutler D, Chan H, Yun J, Raper J . What is a suitable dissolution method for drug nanoparticles?. Pharm Res. 2008; 25(7):1696-701. DOI: 10.1007/s11095-008-9560-0. View

13.

Cao Y, Wang B, Lou D, Wang Y, Hao S, Zhang L . Nanoscale delivery systems for multiple drug combinations in cancer. Future Oncol. 2011; 7(11):1347-57. DOI: 10.2217/fon.11.109. View

14.

Baggarly S, Kemp R, Wang X, Magoun A . Factors associated with medication adherence and persistence of treatment for hypertension in a Medicaid population. Res Social Adm Pharm. 2014; 10(6):e99-e112. DOI: 10.1016/j.sapharm.2014.02.002. View

15.

Hackam D, Khan N, Hemmelgarn B, Rabkin S, Touyz R, Campbell N . The 2010 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2 - therapy. Can J Cardiol. 2010; 26(5):249-58. PMC: 2886555. DOI: 10.1016/s0828-282x(10)70379-2. View

16.

He W, Horn S, Hussain M . Improved bioavailability of orally administered mifepristone from PLGA nanoparticles. Int J Pharm. 2006; 334(1-2):173-8. DOI: 10.1016/j.ijpharm.2006.10.025. View

17.

Jain R . The manufacturing techniques of various drug loaded biodegradable poly(lactide-co-glycolide) (PLGA) devices. Biomaterials. 2000; 21(23):2475-90. DOI: 10.1016/s0142-9612(00)00115-0. View

18.

van Galen K, Nellen J, Nieuwkerk P . The Effect on Treatment Adherence of Administering Drugs as Fixed-Dose Combinations versus as Separate Pills: Systematic Review and Meta-Analysis. AIDS Res Treat. 2014; 2014:967073. PMC: 4168145. DOI: 10.1155/2014/967073. View

19.

Rojas J, Leo E, Pecquet S, Couvreur P, Fattal E . Optimization of the encapsulation and release of beta-lactoglobulin entrapped poly(DL-lactide-co-glycolide) microspheres. Int J Pharm. 1999; 183(1):67-71. DOI: 10.1016/s0378-5173(99)00046-0. View

20.

Italia J, Bhatt D, Bhardwaj V, Tikoo K, Kumar M . PLGA nanoparticles for oral delivery of cyclosporine: nephrotoxicity and pharmacokinetic studies in comparison to Sandimmune Neoral. J Control Release. 2007; 119(2):197-206. DOI: 10.1016/j.jconrel.2007.02.004. View